{'52WeekChange': 0.07968843,
 'SandP52WeekChange': None,
 'address1': '333 Twin Dolphin Drive',
 'address2': 'Suite 600',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 18.29,
 'askSize': 1800,
 'averageDailyVolume10Day': 875862,
 'averageVolume': 1524823,
 'averageVolume10days': 875862,
 'beta': 2.094677,
 'beta3Year': None,
 'bid': 18.27,
 'bidSize': 1200,
 'bookValue': 2.219,
 'category': None,
 'circulatingSupply': None,
 'city': 'Redwood City',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 18.39,
 'dayLow': 17.58,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 7.688,
 'enterpriseToRevenue': 2.977,
 'enterpriseValue': 1295630720,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 17.800142,
 'fiftyTwoWeekHigh': 23.91,
 'fiftyTwoWeekLow': 10.862,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 62700231,
 'forwardEps': 1.22,
 'forwardPE': 14.983606,
 'fromCurrency': None,
 'fullTimeEmployees': 296,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.032360002,
 'heldPercentInstitutions': 1.06198,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/coherus.com',
 'longBusinessSummary': 'Coherus BioSciences, Inc., a commercial-stage '
                        'biotherapeutics company, focuses on the biosimilar '
                        'market worldwide. It markets UDENYCA, a long-acting '
                        'granulocyte-colony stimulating factor, which '
                        'stimulates production of granulocytes in order to '
                        "promote the body's ability to fight infections. The "
                        'company sells UDENYCA in the United States. Its '
                        'clinical-stage product candidates include immunology, '
                        'anti-tumor necrosis factor biosimilar candidates, '
                        'CHS-1420 for adalimumab and CHS-0214 for etanercept, '
                        'which has completed Phase III clinical programs; '
                        'ophthalmology biosimilar candidates, CHS-3351 for '
                        'ranibizumab and CHS-2020 for aflibercept that is in '
                        'preclinical development; and CHS-131, small molecule '
                        'therapeutic candidate and other metabolic conditions. '
                        'Coherus BioSciences, Inc. has collaboration and '
                        'license agreements with Daiichi Sankyo Company, '
                        'Limited; Baxalta Incorporated; Baxalta US Inc.; '
                        'Baxalta GmbH; and Selexis SA. The company was '
                        'formerly known as BioGenerics, Inc. and changed its '
                        'name to Coherus BioSciences, Inc. in April 2012. '
                        'Coherus BioSciences, Inc. was founded in 2010 and is '
                        'headquartered in Redwood City, California.',
 'longName': 'Coherus BioSciences, Inc.',
 'market': 'us_market',
 'marketCap': 1296282368,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_206928583',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 145408992,
 'nextFiscalYearEnd': 1640908800,
 'open': 17.87,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.49,
 'phone': '650 649 3530',
 'previousClose': 18.02,
 'priceHint': 2,
 'priceToBook': 8.237945,
 'priceToSalesTrailing12Months': 2.9789119,
 'profitMargins': 0.33416,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 18.39,
 'regularMarketDayLow': 17.58,
 'regularMarketOpen': 17.87,
 'regularMarketPreviousClose': 18.02,
 'regularMarketPrice': 17.87,
 'regularMarketVolume': 829936,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 70912600,
 'sharesPercentSharesOut': 0.2667,
 'sharesShort': 18915657,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 15421491,
 'shortName': 'Coherus BioSciences, Inc.',
 'shortPercentOfFloat': 0.3298,
 'shortRatio': 13.97,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'CHRS',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 1.957,
 'trailingPE': 9.340828,
 'twoHundredDayAverage': 17.745575,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'c75daf8f-3c65-3d43-b809-ee892c342721',
 'volume': 829936,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.coherus.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94065'}